Zymeworks (ZA8) Stock Overview
A biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ZA8 from our risk checks.
ZA8 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Zymeworks Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.77 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$8.10 |
| Beta | 1.2 |
| 1 Month Change | 4.45% |
| 3 Month Change | 19.21% |
| 1 Year Change | 181.11% |
| 3 Year Change | 155.73% |
| 5 Year Change | -2.19% |
| Change since IPO | 112.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZA8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.4% | 1.5% | 2.9% |
| 1Y | 181.1% | 4.6% | 12.1% |
Return vs Industry: ZA8 exceeded the German Biotechs industry which returned 3.3% over the past year.
Return vs Market: ZA8 exceeded the German Market which returned 11.4% over the past year.
Price Volatility
| ZA8 volatility | |
|---|---|
| ZA8 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: ZA8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ZA8's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 264 | Ken Galbraith | www.zymeworks.com |
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease.
Zymeworks Inc. Fundamentals Summary
| ZA8 fundamental statistics | |
|---|---|
| Market cap | €1.72b |
| Earnings (TTM) | -€69.17m |
| Revenue (TTM) | €90.35m |
Is ZA8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZA8 income statement (TTM) | |
|---|---|
| Revenue | US$105.97m |
| Cost of Revenue | US$137.00m |
| Gross Profit | -US$31.03m |
| Other Expenses | US$50.10m |
| Earnings | -US$81.13m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | -29.29% |
| Net Profit Margin | -76.56% |
| Debt/Equity Ratio | 0% |
How did ZA8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 07:25 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zymeworks Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |
| Mayank Mamtani | B. Riley Securities, Inc. |